The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Artficial sweeteners are everywhere, as many people try to avoid sugar for health reasons. Discover which ones are most ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

Certain additives found in ultra-processed foods are linked to increased type 2 diabetes risk, a new study finds. The mixtures are typically present in broths, dairy desserts, fats, sauces, and sugary ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A new weight-loss pill taken daily could compete with injections like Ozempic, research suggests. Patients, who all were ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.